Simcere Pharmaceutical's (HKG:2096) attributable profit is seen to jump 0.4% to 4.6% to between 718 million yuan and 748 million yuan in 2024 from 715 million yuan in 2023, according to a Friday filing with the Hong Kong Stock Exchange.
Revenue is also forecast to inch up 0.2% to 0.6% to between 6.62 billion yuan and 6.65 billion yuan.
The drug company plans to release fiscal 2024 results in late March.